Page 10 - Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Q4 consolidated PAT declines 26% to Rs 173 cr

Glenmark Pharmaceuticals on Saturday said its consolidated profit after tax declined 26 per cent to Rs 173 crore for the fourth quarter ended March 31, 2022.

Glenmark gets tentative nod from USFDA for generic psoriasis foam

Glenmark Pharmaceuticals on Monday said its US-based arm has received tentative approval from the US health regulator for its generic Calcipotriene and Betamethasone Dipropionate foam used to treat psoriasis. The tentative approval granted to Glenmark Pharmaceuticals Inc, USA (Glenmark) by the US Food & Drug Administration (USFDA) is for Calcipotriene and Betamethasone Dipropionate foam of strength 0.005 per cent/0.064 per cent, the company said in a statement. It is the generic equivalent of Leo Pharma AS' Enstilar foam, it added. Citing IQVIATM sales data for the 12 months ended March 2022, the company said Enstilar foam, 0.005 per cent/0.064 per cent achieved annual sales of approximately USD 115.2 million. Glenmark said its current portfolio consists of 174 products authorised for distribution in the US marketplace and 48 abbreviated new drug applications (ANDAs) are pending approval with the USFDA.

Glenmark launches fixed-dose combination medication for diabetic patients

Glenmark Pharmaceuticals on Monday said it has launched a novel fixed-dose combination (FDC) of Teneligliptin, with Pioglitazone in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement. Diabetes is a key area of focus for Glenmark; a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients, Glenmark Pharmaceuticals Group Vice President & Head, India Formulations Alok Malik said. Glenmark claimed it is the "first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which is approved by the DCGI (Drug Controller General of India)" "This fixed-dose combination will be

Glenmark to conduct clinical trials of its molecule on cancer patients

Glenmark Pharmaceuticals on Monday said its unit has received approval from the DCGI to conduct phase 1 clinical trials of its novel molecule on patients with advanced solid tumors.

Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%

The Nifty Pharma index has crossed its near-term resistance at 13,700, and may spurt another 1.5 per cent.

Nasal spray market heats up as Covid-19 curbs ease, people return to work

Glenmark launches 1st commercially available spray, smaller firms to follow

Glenmark gets nod from US Food & Drug Administration for generic drug

Glenmark Pharmaceuticals on Friday said its US-based unit has received approval from the US health regulator to market Metronidazole Vaginal gel, in the American market. The drug firm has received final approval by the United States Food & Drug Administration (USFDA) for its product which is a generic version of Bausch Health US LLC's MetroGel-Vaginal, the drug firm said in a statement. According to IQVIA sales data for the 12-month period ending November 2021, the MetroGel-Vaginal Gel achieved annual sales of approximately around USD 60.4 million. Glenmark's current portfolio consists of 173 products authorised for distribution in the US marketplace and 46 ANDA's pending approval with the USFDA. In addition to these internal filings, the drug firm continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, Glenmark noted.

Glenmark Pharma inks exclusive licensing agreement with Lotus International

Glenmark Pharmaceuticals Ltd on Thursday said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd

Glenmark Pharma gets tentative FDA nod for generic Regadenoson injection

Glenmark Pharmaceuticals on Monday said its US arm has received tentative approval from the country's health regulator for its generic Regadenoson injection. Regadenoson injection is given during the preparation for a radiologic examination of blood flow through the heart to test for coronary artery disease. The tentative approval granted by the United States Food & Drug Administration (USFDA) to Glenmark Pharmaceuticals Inc, USA (Glenmark) is for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe, the company said in a statement. It is the generic version of Lexiscan injection, 0.4 mg/5 mL (0.08 mg/mL), of Astellas US Inc, it added. Citing IQVIATM sales data for the 12 month period ending November 2021, the company said the Lexiscan Injection, 0.4 mg/5 mL (0.08 mg/mL) market achieved annual sales of approximately USD 659.9 million. The company said its current portfolio consists of 172 products authorized for distribution in the US marketplace and 47 .

Glenmark gets FDA approval for nasal spray for seasonal allergic rhinitis

Glenmark Pharmaceuticals Limited said its subsidiary Glenmark Specialty S.A. has received US FDA approval for nasal spray fixed dose prescription drug for seasonal allergic rhinitis Ryaltris.

Glenmark gets USFDA nod for nasal spray to treat seasonal allergic rhinitis

Glenmark Pharma on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray for the treatment of seasonal allergic rhinitis.

Nandish Shah recommends a Bull spread on Glenmark Pharma for January series

Pharma as a sector looking good on the short term chart, according to Nandish Shah of HDFC Securities.

Stocks to Watch: ITC, Lupin, ABFRL, Glenmark, NBFCs, Tata group stocks

The RBI on Tuesday introduced a prompt corrective action (PCA) framework for large non-banking financial companies (NBFCs)

Glenmark arm nets Rs 180 cr in licensing deal for autoimmune antibody

ISB 880 has the potential to treat underserved patients across a range of autoimmune dermatological diseases

Glenmark, Alembic, Cipla: Pharma stocks on a booster dose this December

Select pharma stocks look good on the technical charts and may jump up to 15 per cent in December. On the fundamental side, fears of Omicron variant spreading may also keep them in news and buzzing

S&P upgrades Glenmark to 'BB' on expectation of conservative debt levels

The outlook is stable reflecting the view that Glenmark will maintain its financial policy such that its FFO-to-debt ratio will remain comfortably above 30%, S&P said

Glenmark Pharma PAT grows 10.1%, revenue grows 6.6% in Sept quarter

Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the second quarter ended Sept 30, 2021.For the second quarter of FY 2021-22, Glenmark's consolidated revenue was at Rs 31,474 Mn as against Rs 29,525 Mn recording an increase of 6.6%.Consolidated EBITDA was at Rs 5,902 Mn in the quarter ended Sept 30, 2021 as against Rs 5,699 Mn in the previous corresponding quarter, registering an increase of 6.8%.Profit after Tax (PAT) was at Rs 2,577 Mn for the quarter ended Sept 30, 2021 as compared to Rs 2,340 Mn in the previous corresponding quarter, recording a growth of 10.1%."We delivered yet another quarter of consistent performance, both in revenue growth and profitability. We have continued to perform well in our core therapy areas and launched differentiated products." said Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd.He further added, "We have substantially reduced our ...

Glenmark launches unique fixed dose combination drug for diabetes

Glenmark said it has become the first company in the world to launch the fixed dose combination drug in India

Stocks to Watch: Zee, HFCL, Tata Motors, Glenmark, JSW Steel, Vakrangee

Six companies are slated to announce earnings today including BEPL, DRC Systems India, JTL Infra, and Ind Bank Housing

Drug makers Glenmark, Aurobindo Pharma recall products in US market

Glenmark and Aurobindo Pharma are recalling multiple products in the US market due to various reasons like deviation from standard manufacturing protocols and presence of foreign substance